Moderately to severely active ulcerative colitis research hub
14 indexed studies · 12 currently recruiting
- recruitingTherapeutic exploratory (Phase II)
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-2)
This study is testing a new capsule medicine called MORF-057 for adults with moderate to severe ulcerative colitis. Researchers want to see if three different doses can safely reduce gut inflammation, improve common symptoms like bleeding and frequent bowel movements, and help the gut lining heal over 52 weeks.
Italy · Hungary · Latvia - recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitis
This study is testing a new medicine, ABX464, for people with moderate to severe ulcerative colitis. Researchers want to see if it helps improve the gut lining and reduces symptoms after 8 weeks, and if it's safe to use.
France · Spain · Italy - recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitis
This study is testing a new medicine, ABX464, for people aged 18 and over with moderate to severe ulcerative colitis. It aims to see if the medicine helps improve symptoms and gut healing more than a dummy medicine (placebo), and if it's safe to use.
France · Spain · Germany - recruitingTherapeutic confirmatory (Phase III)
I6T-MC-AMBZ - A Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab
This study looks at a new medicine called mirikizumab for adults with a bowel condition called ulcerative colitis. It specifically checks if the medicine helps reduce how often people feel an urgent need to go to the toilet over 12 weeks.
Austria · Slovakia · Czechia - recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab as Open-label Intravenous Induction Treatment Followed by Randomized Double-blind Subcutaneous Ustekinumab Maintenance in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis
This study is looking at a medicine called ustekinumab (Stelara) for children and teenagers with a gut condition called ulcerative colitis. It hopes to see if it's safe and effective in helping them feel better and stay well, compared to a dummy medicine.
Germany · Hungary · Belgium - recruitingTherapeutic confirmatory (Phase III)
I6T-MC-AMBA - A Multicenter, Phase 3, Open-Label Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age with Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine, Mirikizumab (also called Omvoh), for children and teenagers aged 2 to under 18 who have moderate to severe ulcerative colitis. We want to see how well it works and if it's safe to help them feel better.
Belgium · Portugal · Poland - recruitingHuman Pharmacology (Phase I)- Other
A Phase 1, 2-part, open-label, single-sequence study to investigate the effect of single and multiple doses of obefazimod on the pharmacokinetics of rosuvastatin in healthy male participants.
This study is looking at how a new medicine for ulcerative colitis, called obefazimod, might affect how another common heart medicine, rosuvastatin, works in healthy men. It’s an early-stage study to understand how these medicines interact in the body.
France - recruitingHuman Pharmacology (Phase I)- Other
A Phase I study to evaluate the pharmacokinetics, safety and tolerability of multiple oral doses of obefazimod in participants with renal impairment and matched normal kidney function.
This study looks at a new medicine called obefazimod for people with ulcerative colitis. It checks how the body handles the medicine and if it's safe when taken multiple times, especially in people with kidney problems compared to those with healthy kidneys.
Germany - recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Clinical Efficacy and Safety of VTX002 in Subjects with Moderately to Severely Active Ulcerative Colitis
This study is testing a new medicine, VTX002, for people with moderate to severe ulcerative colitis. Researchers want to see if it helps reduce symptoms and improve the condition, compared to a dummy pill.
Germany · Czechia · Slovakia - recruitingTherapeutic exploratory (Phase II)
A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Tolerability of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-1)
This study is testing a new medicine, MORF-057, for adults with ulcerative colitis that is active. Researchers want to see if it helps improve their symptoms and body changes, how safe it is, and if people can tolerate it well over 12 weeks.
Poland - recruitingPhase III
A study of JNJ-78934804 in participants with moderately to severely active ulcerative colitis (DUET ENCORE-UC)
This clinical trial is testing a new combined injection called JNJ-78934804 for adults with moderate to severe ulcerative colitis. Researchers want to see if combining two different medicines into one injection works better and is safer at reducing gut inflammation than using a single medicine on its own.
United Kingdom · England · Scotland - active not recruitingPHASE3
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
This study is looking into a new medication called Afimkibart for people aged 16-80 with ulcerative colitis that is moderately to severely active. It aims to see how well it works and if it's safe compared to a dummy drug. We hope it could be a new treatment option.
United States · Argentina · Australia - recruitingPHASE3
A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis
This study is looking into a new medication called Afimkibart for children aged 2-17 with moderate to severe ulcerative colitis. It aims to see if the medication is safe, helps them feel better, and works well compared to a dummy treatment.
United States · Australia · Brazil - active not recruitingPHASE3
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
This study is testing a new medicine called Afimkibart for people with moderate to severe ulcerative colitis. It aims to see how well it works and if it's safe compared to a dummy drug. The study is for adults aged 16 to 80 who haven't found existing treatments helpful.
United States · Argentina · Australia